Here is the latest shareholding Pattern of ZYDUS LIFESCIENCES. For more details, see the ZYDUS LIFESCIENCES financial fact sheet and ZYDUS LIFESCIENCES share price and chart. For a sector overview, read our pharmaceuticals sector report.
No. of Mths Qtr. Ending |
3
Jun-20 |
3
Sep-20 |
3
Dec-20 |
3
Mar-21 |
3
Jun-21 |
3
Sep-21 |
3
Dec-21 |
3
Mar-22 |
||
---|---|---|---|---|---|---|---|---|---|---|
Indian Promoters | % | 74.88 | 74.88 | 74.88 | 74.88 | 74.88 | 74.88 | 74.88 | 74.88 | |
Foreign Promoters | % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Total Promoters | % | 74.88 | 74.88 | 74.88 | 74.88 | 74.88 | 74.88 | 74.88 | 74.88 | |
Mutual Funds | % | 7.47 | 7.27 | 7.54 | 6.41 | 5.83 | 4.79 | 4.85 | 5.55 | |
Financial institution/Banks/Insurance | % | 5.04 | 5.07 | 4.01 | 4.71 | 4.59 | 6.43 | 6.93 | 7.23 | |
Government | % | 0.19 | 0.19 | 0.19 | 0.19 | 0.07 | 0.07 | 0.07 | 0.08 | |
FII | % | 4.56 | 4.38 | 5.24 | 5.23 | 4.65 | 4.11 | 3.79 | 2.53 | |
Other | % | 0.08 | 0.16 | 0.17 | 0.18 | 0.08 | 0.03 | 0.02 | 0.05 | |
Total Institution | % | 17.34 | 17.07 | 17.15 | 16.72 | 15.22 | 15.43 | 15.66 | 15.44 | |
Bodies Corporate | % | 0.93 | 0.87 | 0.92 | 0.90 | 1.01 | 0.94 | 0.90 | 0.87 | |
Individuals | % | 5.76 | 5.89 | 5.78 | 6.16 | 7.31 | 7.38 | 7.40 | 7.81 | |
NRIs/OCBs | % | 0.26 | 0.27 | 0.27 | 0.32 | 0.32 | 0.31 | 0.27 | 0.35 | |
ADR/GDR | % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Others | % | 0.83 | 1.02 | 1.00 | 1.02 | 1.26 | 1.06 | 0.89 | 0.66 | |
Total Non-Institution | % | 7.78 | 8.05 | 7.97 | 8.40 | 9.90 | 9.69 | 9.46 | 9.69 | |
Total Public | % | 25.00 | 25.00 | 25.00 | 25.00 | 25.00 | 25.00 | 25.00 | 25.00 | |
Grand Total | % | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | |
Pledged Promoter Holding | % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
![]() |
More Pharmaceuticals Company Shareholding Pattern: LUPIN DR. REDDYS LAB AUROBINDO PHARMA CIPLA SUN PHARMA
Indian share markets remained in the bear grip throughout the trading session today tracking extremely weak global cues.
A look into the company's quarter four financial performance.
These companies are likely to benefit the most from Covid-19 vaccines.
During Q4, there were many changes to the products forming part of Dr Reddy's generics and proprietary products segments.
The pandemic has opened up new opportunities for the Indian pharmaceutical sector. Which company is set to benefit from it?
For the Nifty pharma index, it seems as if bulls are losing ground as they witness multiple bearish candlestick patterns.
More Views on NewsWe are just two months into 2022 and several penny stocks that we track have already surged 5x.
Debt free penny stocks are vital when it's a question of portfolio diversification in a volatile market. They can potentially offer good profitability in the long run.
A step-by-step method to pick the best penny stocks for the long term.
These penny stocks can become future multibaggers. Watch out for them.
Rising electricity consumption provides a lot of scope for growth. Which company has a better chance at capturing it?
More